Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
65.85
-0.30 (-0.45%)
At close: Oct 27, 2025, 4:00 PM EDT
65.50
-0.35 (-0.53%)
After-hours: Oct 27, 2025, 6:54 PM EDT
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Halozyme Therapeutics stock have a consensus rating of "Buy" and an average price target of $73.18, which forecasts a 11.13% increase in the stock price over the next year. The lowest target is $53 and the highest is $90.
Price Target: $73.18 (+11.13%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Halozyme Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 3 | 3 |
| Buy | 2 | 2 | 2 | 4 | 4 | 4 |
| Hold | 5 | 5 | 5 | 3 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 9 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold Maintains $63 → $65 | Hold | Maintains | $63 → $65 | -1.29% | Oct 27, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $80 → $79 | Buy | Maintains | $80 → $79 | +19.97% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +36.67% | Oct 15, 2025 |
| Leerink Partners | Leerink Partners | Sell → Hold Upgrades $70 | Sell → Hold | Upgrades | $70 | +6.30% | Oct 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $85 → $90 | Strong Buy | Maintains | $85 → $90 | +36.67% | Oct 2, 2025 |
Financial Forecast
Revenue This Year
1.35B
from 1.02B
Increased by 32.47%
Revenue Next Year
1.67B
from 1.35B
Increased by 24.01%
EPS This Year
6.28
from 3.43
Increased by 83.08%
EPS Next Year
8.14
from 6.28
Increased by 29.55%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.4B | 1.8B | |||
| Avg | 1.3B | 1.7B | |||
| Low | 1.3B | 1.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.1% | 31.3% | |||
| Avg | 32.5% | 24.0% | |||
| Low | 26.0% | 14.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.63 | 8.93 | |||
| Avg | 6.28 | 8.14 | |||
| Low | 5.93 | 7.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 93.2% | 42.1% | |||
| Avg | 83.1% | 29.6% | |||
| Low | 72.9% | 12.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.